New England Journal of Medicine· 2014Q1

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini, Elizabeth A. Fagan et al.

3,976citations
Q1SCImago
2014year

Short summary

A Phase 3 trial (n=555) found that pirfenidone reduced disease progression in idiopathic pulmonary fibrosis (IPF) patients by 47.9% compared to placebo, as measured by FVC decline or death, and improved progression-free survival.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine